 | Up a level |
Felip, E. and Cho, B. C. and Gutierrez, V and Alip, A. and Besse, B. and Lu, S. and Spira, A. I. and Girard, N. and Califano, R. and Gadgeel, S. M. and Yang, J. C-H. and Yamamoto, S. and Azuma, K. and Kim, Y. J. and Lee, K. -H. and Danchaivijitr, P. and Ferreira, C. G. and Cheng, Y. and Sendur, M. A. N. and Chang, G. -C. and Wang, C. -C. and Prabhash, K. and Shinno, Y. and Stroyakovskiy, D. and Paz-Ares, L. and Rodriguez-Cid, J. R. and Martin, C. and Campelo, M. R. G. and Hayashi, H. and Nguyen, D. and Tomasini, P. and Gottfried, M. and Dooms, C. and Passaro, A. and Schuler, M. and Gelatti, A. C. Z. and Owen, S. and Perdrizet, K. and Ou, S. -H. I. and Curtin, J. C. and Zhang, J. and Gormley, M. and Sun, T. and Panchal, A. and Ennis, M. and Fennema, E. and Bauml, J. M. and Daksh, M. and Sethi, S. and Lee, S. -H. (2024) Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small-cell lung cancer with biomarkers of high-risk disease: a secondary analysis from MARIPOSA. Annals of Oncology, 35 (9). pp. 805-816. ISSN 0923-7534, DOI https://doi.org/10.1016/j.annonc.2024.05.541.
